Isabell Witzel

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Eric P. Winer, Oleg Lipatov, Seock‐Ah Im et al. · The Lancet Oncology · 2021 · 493 citations

Medicine, Oncology, Pharmacology +14

Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification

Michael T. Parsons, Emma Tudini, Hongyan Li et al. · Human Mutation · 2019 · 152 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

W. Eiermann, Mahdi Rezai, Sherko Kümmel et al. · Annals of Oncology · 2012 · 146 citations · Full text

Medicine, Oncology, Breast Oncology +16

Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer

Christine Schröder, Isabell Witzel, Volkmar Müller et al. · Journal of Cancer Research and Clinical Oncology · 2011 · 110 citations · Full text

Life Sciences, Cell Biology, Oncology +16

Prognostic relevance of glycosylation-associated genes in breast cancer

Karin Milde‐Langosch, Thomas Karn, Marcus Schmidt et al. · Breast Cancer Research and Treatment · 2014 · 99 citations

Life Sciences, Molecular Biology, Oncology +16